Abstract: As a new type of drug, small molecule targeted drugs, such as Janus kinase (JAK) inhibitors, phosphodiesterase inhibitors (PDE) inhibitors, and protein kinase C (PKC) inhibitors, are at the stage of clinical trials for the treatment of skin diseases. In order to further improve the efficacy, reduce adverse reactions and treatment costs, small molecular targeted drugs which block the specific cytokines have applied in many refractory skin diseases. The update of small molecular targeted drugs in the treatment for dermatosis is reviewed in this article.

Key words: dermatology, small-molecule drugs, treatment